Valeant Dips Below $20 as Brexit Exacerbates Concerns

Updated on
  • Exchange rates could hurt Valeant sales outside U.S.
  • Drugmaker’s stock has not fallen below $20 since 2010

Is Anything Else Is Impacting Valeant Besides Brexit?

Valeant Pharmaceuticals International Inc.’s shares slipped below $20 Monday as investor worries about the future of the heavily indebted drugmaker continued to mount in the wake of U.K.’s historic vote to exit the European Union.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.